
Sign up to save your podcasts
Or
This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.
In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
3.7
5353 ratings
This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.
In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.
Like what you hear? Get 20 episodes/month with CME/MOC credit! www.acc.org/ACCEL
132 Listeners
322 Listeners
160 Listeners
862 Listeners
496 Listeners
272 Listeners
3,321 Listeners
87 Listeners
135 Listeners
1,081 Listeners
39 Listeners
186 Listeners
321 Listeners
416 Listeners
35 Listeners